Differential Effects of Small Molecule Inhibitors on the Intracellular Chlamydia Infection

Abstract

Chlamydia is the most reported cause of bacterial, sexually transmitted infection in the United States. This bacterium infects human cells and reproduces within a cytoplasmic inclusion via an unusual developmental cycle involving two specialized chlamydial forms.

Alternative strategies for Chlamydia treatment: Promising non-antibiotic approaches

“…Similarly, the small-molecule inhibitor H89 decreases the production of chlamydial progeny by reducing RB replication and interfering with RB to EB conversion (Muñoz et al, 2021 ). In addition, a molecule inhibitor, MK2206, can alter host lipid synthesis and cholesterol transfer to reduce the conversion of RB to EB (Muñoz et al, 2022 ). Based on these studies, small-molecule inhibitors interfere with the development and infection of Chlamydia by reducing the production of EB, altering inclusion size, and disrupting RB to EB conversion.…”